Core Viewpoint - China Biologic Products (01177) has received acceptance for the clinical trial application (IND) of its innovative drug TQB3142, a Bcl-xL PROTAC molecule, from the National Medical Products Administration (NMPA) in China, aimed at treating malignant tumors [1] Group 1: Product Details - TQB3142 targets the degradation of the Bcl-xL protein through the ubiquitin-proteasome system, which alleviates its inhibition on tumor cell apoptosis, thereby activating the Caspase cascade and inducing programmed cell death in tumor cells [1] - Research indicates that TQB3142 demonstrates significant anti-tumor activity in various transplant tumor models and has a lower risk of platelet toxicity compared to similar candidate drugs, offering a better therapeutic window with controllable metabolic risks [1] Group 2: Market Position - Currently, there are no approved Bcl-xL inhibitors available globally, making TQB3142 a novel mechanism anti-tumor drug [1] - The drug's molecular design optimization allows it to maintain degradation activity while reducing blood toxicity risks, potentially providing new treatment options for patients with malignant tumors [1]